Company* (Symbol) | Product | Description | Indication | Action/Date** |
CANCER | ||||
Aphton Corp. (APHT) | Anticancer therapeutic designed to induce a directed antibody response against gastrin and other gastrin-related growth factors | Gastric cancer | Filed investigational new drug (IND) application (12/7) | |
G.D. Searle & Co. Inc. (a unit of Monsanto Co.;NYSE:MTC) | Celebrex | Celecoxib; COX-2 enzyme inhibitor | Familial adenomatous polyposis | FDA granted adjunctive treatment approval (12/23) |
Guilford Pharmaceuticals Inc. (GLFD) | Paclimer | Injectable, biopolymer-based microspheres formulation of paclitaxel | Ovarian cancer | Filed IND application (12/15) |
Ilex Oncology Inc. (ILXO), Millennium Pharmaceuticals Inc. (MLNM) and Berlex Laboratories (a unit of Schering AG, Germany) | Campath | Alemtuzumab, humanized monoclonal antibody | B-cell chronic lymphocytic leukemia | Filed biologics license application (12/23) |
LifeTime Pharmaceuticals* | Beta LT | Anticancer therapeutic | Myeloma and B-cell lymphoma | Received clearance to proceed with Phase I/II trials (12/2) |
Ligand Pharmaceuticals Inc. (LGND) | Targretin gel | 1% topical formulation of bexarotene | Early-stage cutaneous T-cell lymphoma | Filed new drug application (NDA) (12/9) |
Targretin capsules | Bexarotene; synthetic retinoid X receptors; oral formulation | Advanced-stage cutaneous T-cell lymphoma | Oncologic Drugs Advisory Committee (ODAC) recommended marketing approval (12/13) | |
Lorus Therapeutics Inc. (Canada; TSE:LOR) | GTI 2040 | Antisense anticancer therapeutic | Various cancers | Received clearance to proceed with Phase I/II trials (12/7) |
Scotia Holdings plc (UK; LSE:SOH) | Foscan | Photodynamic cancer therapeutic | Various cancers | NDA accepted for review (12/2) |
CENTRAL NERVOUS SYSTEM | ||||
Titan Pharmaceuticals Inc. (AMEX:TTP) | Spheramine | Cell therapy product that uses human retinal pigmented epithelial cells that secrete dopamine | Parkinson's disease | Received clearance to commence patient enrollment in Phase I/II trial (12/6) |
DIABETES | ||||
Organogenesis Inc. (AMEX:ORG) | Apligraf | Living human skin equivalent, composed of living human keratinocytes and fibroblasts | Diabetic foot ulcers | Filed premarket approval application (12/22) |
INFECTION | ||||
Agouron Pharmaceuticals Inc. (a subsidiary of the Warner-Lambert Co.; NYSE:WLA) | Viracept | Nelfinavir mesylate; synthetic small-molecule HIV protease inhibitor | HIV infection | FDA approved twice-daily dosing based on Phase III trial results (12/1) |
Triangle Pharmaceuticals Inc. (VIRS) | Coactinon | Emivirine; non-nucleoside reverse transcriptase inhibitor | HIV infection | FDA advised Triangle it needs to conduct additional Phase III trials (12/10) |
Vertex Pharmaceuticals Inc. (VRTX) and Glaxo Wellcome (NYSE:GLX) | VX-175/GW433908 | HIV protease inhibitor; prodrug of amprenavir | HIV infection | Received fast-track designation (12/16) |
MISCELLANEOUS | ||||
Genentech Inc. (NYSE:DNA) and Alkermes Inc. (ALKS) | Nutropin and Nutropin AQ | Somatropin of rDNA origin for injection | Young adults with childhood-onset growth hormone deficiency | FDA approved clinical trial efficacy results (12/2) |
Immunex Corp. (IMNX) | Novantrone | Mitoxantrone for injection concentrate | Secondary progressive multiple sclerosis | FDA advisory committee announced a review of data from the company's NDA (12/6) |
Notes:
* Indicates a privately held company.
** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place.
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.
AMEX = American Stock Exchange; TSE = Toronto Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange